
Skepticism of a startup's claimed drug combo that mimics young blood for aging
Louis comments on a startup claiming a two-drug combination replicates the effect of young blood. He says the underlying parabiosis science is real but the commercial rollout, based on anecdotes and a pay-to-play trial, endangers the field's reputation. He speculates the drugs are anti-inflammatory agents targeting cytokines such as IL-11 and TGF-beta.